Lung cancer is the most common malignant tumor in the world in terms of morbidity and mortality. Among them, lung adenocarcinoma is the most common pathological type. The combined modality therapy and whole-process management of lung adenocarcinoma play an important role in improving the prognosis. We summarized in this article the comprehensive treatment and the whole management process of a patient with lung adenocarcinoma, and reviewed the literatures on the diagnosis and treatment experience of this patient. A 48-year-old male was diagnosed as lung cancer of right middle lobe. He underwent radical resection of cancer via video-assisted thoracoscopic surgery (VATS). The pathological diagnosis was lung adenocarcinoma. Recurrence occurred one year after operation. Iressa was given to the patient only for two months because of the disease progression. Platinum combined with pemetrexed regimen was used for 8 courses. Disease progress was evaluated again. Avastin plus taxotere combined with cisplatin regimen was given for 5 courses but forced to stop because of renal insufficiency. Liquid test was T790M (+). Osimertinib was given to this patient who has been in stable condition from then. Individualized assessment, combined modality therapy and whole-process management of non-small cell lung cancer are important to improve the prognosis of patients with non-small cell lung cancer.